Bardoxolone methyl
Sponsors
Reata Pharmaceuticals, Inc., Biogen, Kyowa Kirin Co., Ltd., NYU Langone Health
Conditions
Acute Interstitial PneumonitisAdvanced Solid TumorsAlport SyndromeAutosomal Dominant Polycystic KidneyChronic Kidney Disease Alport Syndrome Autosomal Dominant Polycystic KidneyChronic Kidney DiseasesCovid19Cryptogenic Organizing Pneumonia
Phase 1
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
TerminatedNCT00529113
Start: 2007-09-30End: 2009-11-01Updated: 2025-05-29
RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
CompletedNCT00529438
Start: 2006-04-30End: 2008-12-01Updated: 2025-05-28
A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl
CompletedNCT01461161
Start: 2011-10-31End: 2011-12-31Updated: 2025-05-29
A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects
CompletedNCT01503866
Start: 2011-12-01End: 2011-12-31Updated: 2025-05-29
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
TerminatedNCT01549769
Start: 2012-04-30End: 2013-10-31Updated: 2025-05-29
Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes
WithdrawnNCT01551446
Start: 2012-04-30End: 2012-11-30Updated: 2025-05-29
Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function
CompletedNCT01563562
Start: 2012-04-30End: 2012-11-30Updated: 2025-05-29
A Study of RTA 402 in Obese Adults
CompletedNCT04018339
Start: 2019-08-20End: 2020-06-18Updated: 2020-06-23
A Clinical Pharmacology Study of Bardoxolone Methyl in Healthy Adults
CompletedNCT04023903
Start: 2019-04-04End: 2019-06-14Updated: 2020-02-05
Phase 2
A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus
WithdrawnNCT01655186
Start: 2012-09-30End: 2012-10-31Updated: 2025-05-29
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
CompletedNCT02036970
Start: 2014-05-31End: 2018-05-16Updated: 2025-06-10
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
CompletedNCT03019185
Start: 2017-03-02End: 2020-10-30Updated: 2025-06-11
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
CompletedNCT04494646
Start: 2020-09-08End: 2021-01-08Updated: 2022-01-13
Phase 3
Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
TerminatedNCT03068130
Start: 2017-04-18End: 2020-09-30Updated: 2025-06-11
A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study
TerminatedNCT03550443
Start: 2018-05-30End: 2023-07-31Updated: 2023-09-26
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
TerminatedNCT03749447
Start: 2019-03-08End: 2023-08-23Updated: 2025-06-03
An extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension
Active, not recruitingNL-OMON49960
Start: 2017-08-30Target: 5Updated: 2024-02-28
An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients with Chronic Kidney Disease
Active, not recruitingJPRN-UMIN000039943
Start: 2019-03-08Target: 1030Updated: 2026-06-29